Assessment of the effects of gastric degradation-protected pea protein extract on mucosal satiety hormone release by human duodenal tissue
- Conditions
- 10003018ObesitasObesityoverweight
- Registration Number
- NL-OMON38483
- Lead Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 31
Men/women, healthy human beings, age 18-70 years, BMI between 18.5 and 24.9 kg/m2, consistently stable body weight for at least 6 months (+/- 2 kg)
Type 2 diabetes mellitus (defined as fasting plasma glucose >= 7.0 mmol/L); Gastroenterological diseases or abdominal surgery (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgment of the principle investigator); Cardiovascular diseases, cancer, liver or kidney malfunction, auto-immune diseases, disease with a life expectancy shorter than 5 years; Abuse of products; alcohol (>20 alcoholic consumptions per week) and drugs; Smoking; Plans to lose weight or following a hypocaloric diet; Use of any medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing; Regular use of laxation products; Use of antibiotics in the 90 days prior to the start of study. Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 90 days prior to the study; Known pregnancy, lactation (checked by a pregnancy test before start of study); Blood donation within 3 months before study period; Self-admitted HIV-positive state
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is the effect of five different protected pea protein<br /><br>extracts on intestinal satiety hormone release (CCK, GLP-1, PYY).</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoint is the degradability of the different prototypes by human<br /><br>gastric fluid, tested in an in vitro setting.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.